Drug, device ties capped at $50K for docs on FDA ad boards
Compliance Monitor, April 4, 2007
Want to receive articles like this one in your inbox? Subscribe to Compliance Monitor!
The FDA has proposed stricter conflict of interest rules that set a grant or fee cap of $50,000 for experts who serve on the FDA's advisory committees. Outsides experts with more than $50,000 in ties to drug and device companies regulated by the FDA would be barred from advising the agency under draft guidelines issued last week.
The guidelines also would limit the participation of experts if they had held a generally disqualifying financial interest within the preceding year. The FDA has provided a flowchart for agency employees to follow when seeking potential advisers.
The new policy would affect a "significant number" of present board members, FDA Acting Commissioner Randall W. Lutter told The New York Times. Last month, former FDA Commissioner Lester Crawford pleaded guilty to lying about owning stock in FDA-regulated companies. He received three years' supervised probation and was fined about $90,000.
Want to receive articles like this one in your inbox? Subscribe to Compliance Monitor!
Related Products
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Identify potential Medicaid RAC target areas
- HIPAA Q&A: Level of encryption needed for email
- Topic: CMS, OESS post new security compliance review information, checklist
- Capturing all necessary codes for IUD insertion and removal can be challenging
- What does case-mix index mean to you?
- OB services: Coding inside and outside of the package
- QA:Coding multiple initial infusions
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- HIPAA Q&A: Level of encryption needed for email
- Q&A: Follow CMS' coding guidelines when using modifier -25
- What does case-mix index mean to you?
- Catch up on what's new with injections and infusions
- CMS has reformulated payments for some bilateral procedures
- New conflicts of interest create new challenges
- Q/A. One injection code or two?
- ED-to-inpatient transfers are flawed with safety gaps
- Searched
